Eur Respir J. 2012 Apr;39(4):799-801.
Towards prognostic biomarkers in pulmonary arterial hypertension.
Source
Clinical Pharmacology Unit, Inserm CIC03, Centre d'Investigation Clinique de Grenoble, CHU de Grenoble, 38043 Grenoble Cedex 09, France. E-mail: Jean-Luc.Cracowski@ujf-grenoble.fr.
"The most reliable way to assess the clinical impact of a therapeutic intervention in pulmonary arterial hypertension (PAH) is through its effect on well-defined clinical end-points, such as mortality. However, this standard is often impractical because of the long period and large number of patients required to reach these clinical end-points, and substitutes, such as the 6-min walking distance, are often used. Biomarkers may also be reliable substitutes for clinical end-points,..."
No comments:
Post a Comment